In addition, the lack of hormone receptor expression renders TNBC tumors refractory to the targeted therapeutics currently being implemented for the treatment of hormone receptor positive breast cancer subtypes, essentially limiting treatment options to chemotherapy. This evidence concerns the gene NR4A1 and breast carcinoma.